225 related articles for article (PubMed ID: 23634290)
1. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer.
Krishnamurthy S; Bischoff F; Ann Mayer J; Wong K; Pham T; Kuerer H; Lodhi A; Bhattacharyya A; Hall C; Lucci A
Cancer Med; 2013 Apr; 2(2):226-33. PubMed ID: 23634290
[TBL] [Abstract][Full Text] [Related]
2. Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients.
Rack B; Zombirt E; Trapp E; Jückstock J; Andergassen U; Neugebauer J; Kost B; Weissenbacher T; Jeschke U; Schindlbeck C; Janni W; Alunni-Fabbroni M
Oncology; 2016; 90(4):232-8. PubMed ID: 26937631
[TBL] [Abstract][Full Text] [Related]
3. HER2-positive DTCs/CTCs in breast cancer.
Hartkopf AD; Banys M; Fehm T
Recent Results Cancer Res; 2012; 195():203-15. PubMed ID: 22527508
[TBL] [Abstract][Full Text] [Related]
4. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Krishnamurthy S; Cristofanilli M; Singh B; Reuben J; Gao H; Cohen EN; Andreopoulou E; Hall CS; Lodhi A; Jackson S; Lucci A
Cancer; 2010 Jul; 116(14):3330-7. PubMed ID: 20564098
[TBL] [Abstract][Full Text] [Related]
5. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
Fehm T; Hoffmann O; Aktas B; Becker S; Solomayer EF; Wallwiener D; Kimmig R; Kasimir-Bauer S
Breast Cancer Res; 2009; 11(4):R59. PubMed ID: 19664291
[TBL] [Abstract][Full Text] [Related]
6. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
[TBL] [Abstract][Full Text] [Related]
7. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.
Daskalaki A; Agelaki S; Perraki M; Apostolaki S; Xenidis N; Stathopoulos E; Kontopodis E; Hatzidaki D; Mavroudis D; Georgoulias V
Br J Cancer; 2009 Aug; 101(4):589-97. PubMed ID: 19623181
[TBL] [Abstract][Full Text] [Related]
8. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM
Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900
[TBL] [Abstract][Full Text] [Related]
9. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
[TBL] [Abstract][Full Text] [Related]
10. Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer.
Cao S; Li Y; Li J; Li CF; Zhang W; Yang ZQ; Meng SD
Oncol Rep; 2010 Feb; 23(2):423-8. PubMed ID: 20043103
[TBL] [Abstract][Full Text] [Related]
11. Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score.
Singh P; Tevis SE; Hall CS; Meas S; Hwang RF; Lucci A
Breast Cancer Res Treat; 2020 Dec; 184(3):683-687. PubMed ID: 32888140
[TBL] [Abstract][Full Text] [Related]
12. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
Jaeger BAS; Neugebauer J; Andergassen U; Melcher C; Schochter F; Mouarrawy D; Ziemendorff G; Clemens M; V Abel E; Heinrich G; Schueller K; Schneeweiss A; Fasching P; Beckmann MW; Scholz C; Friedl TWP; Friese K; Pantel K; Fehm T; Janni W; Rack B
PLoS One; 2017; 12(6):e0173593. PubMed ID: 28586395
[TBL] [Abstract][Full Text] [Related]
13. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.
Pestrin M; Bessi S; Galardi F; Truglia M; Biggeri A; Biagioni C; Cappadona S; Biganzoli L; Giannini A; Di Leo A
Breast Cancer Res Treat; 2009 Dec; 118(3):523-30. PubMed ID: 19597704
[TBL] [Abstract][Full Text] [Related]
14. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
[TBL] [Abstract][Full Text] [Related]
15. Enrichment and Molecular Analysis of Breast Cancer Disseminated Tumor Cells from Bone Marrow Using Microfiltration.
Pillai SG; Zhu P; Siddappa CM; Adams DL; Li S; Makarova OV; Amstutz P; Nunley R; Tang CM; Watson MA; Aft RL
PLoS One; 2017; 12(1):e0170761. PubMed ID: 28129357
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients.
Hartkopf AD; Wallwiener M; Hahn M; Fehm TN; Brucker SY; Taran FA
Cancer Res Treat; 2016 Jan; 48(1):115-24. PubMed ID: 25687853
[TBL] [Abstract][Full Text] [Related]
17. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.
Fehm T; Becker S; Duerr-Stoerzer S; Sotlar K; Mueller V; Wallwiener D; Lane N; Solomayer E; Uhr J
Breast Cancer Res; 2007; 9(5):R74. PubMed ID: 17963511
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
[TBL] [Abstract][Full Text] [Related]
19. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.
Munzone E; Nolé F; Goldhirsch A; Botteri E; Esposito A; Zorzino L; Curigliano G; Minchella I; Adamoli L; Cassatella MC; Casadio C; Sandri MT
Clin Breast Cancer; 2010 Oct; 10(5):392-7. PubMed ID: 20920984
[TBL] [Abstract][Full Text] [Related]
20. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
[No Abstract] [Full Text] [Related]
[Next] [New Search]
